CommercialCoverageMedium impact
Tumor Chemoresistance Assays (CPB 0758, reviewed 2026-10-21)
Aetna·Oncology, Pathology, Hematology·Medical Policy
We identified it
Oct 23, 2026
Summary
Aetna's Clinical Policy Bulletin 0758 (reviewed 2026-10-21) confirms that tumor chemoresistance assays, including the Onco4D biodynamic chemotherapy selection assay, remain classified as experimental, investigational, or unproven due to insufficient evidence that these assays improve clinical outcomes. Billing teams should not bill for these assays under Aetna coverage; claims will be denied.
Action Required
Billing team should verify current applicability of this policy and confirm whether the practice's billing system currently blocks or flags claims for tumor chemoresistance assays (CPT codes 0083U, 87230, 88104, 88305, 88313, 88358, 89050, 88230, 88233, 88235, 88237, 88239) submitted to Aetna for patients with neoplasm diagnoses (ICD-10: C00.0–D49.9) or antineoplastic chemotherapy encounters (Z51.11–Z51.12). No claims for these assays should be submitted to Aetna for coverage; educate providers that Onco4D and other chemoresistance assays are non-covered services under this policy. Retain this bulletin's reference for denial appeals and patient financial counseling.